The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: CpG island methylator phenotype (CIMP)- high colorectal cancers (CRCs) have distinct clinicopathological features from their CIMP-low/negative CRC counterparts. However, controversy exists regarding the prognosis of CRC according to the CIMP status. Therefore, this study examined the prognosis of Korean patients with colon cancer according to the CIMP status. Methods: Among a previous cohort population with CRC, a total of 154 patients with colon cancer who had available tissue for DNA extraction were included in the study. CIMP-high was defined as ≥3/5 methylated markers using the five-marker panel (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1). Results: CIMP-high and CIMP-low/negative cancers were observed in 27 patients (17.5%) and 127 patients (82.5%), respectively. Multivariate analysis adjusting for age, gender, tumor location, tumor stage and CIMP and microsatellite instability (MSI) statuses indicated that CIMP-high colon cancers were associated with a significant increase in colon cancer-specific mortality (hazard ratio [HR], 3.23; 95% confidence interval [CI], 1.20 to 8.69; p=0.02). In microsatellite stable cancers, CIMP-high cancer had a poor survival outcome compared to CIMP-low/negative cancer (HR, 2.91; 95% CI, 1.02 to 8.27; p=0.04). Conclusions: Regardless of the MSI status, CIMP-high cancers had poor survival outcomes in Korean patients.
Abstract
Background/Aims: CpG island methylator phenotype (CIMP)- high colorectal cancers (CRCs) have distinct clinicopathological features from their CIMP-low/negative CRC counterparts. However, controversy exists regarding the prognosis of CRC according to the CIMP status. Therefore, this study examined the prognosis of Korean patients with colon cancer according to the CIMP status. Methods: Among a previous cohort population with CRC, a total of 154 patients with colon cancer who had available tissue for DNA extraction were included in the study. CIMP-high was defined as ≥3/5 methylated markers using the five-marker panel (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1). Results: CIMP-high and CIMP-low/negative cancers were observed in 27 patients (17.5%) and 127 patients (82.5%), respectively. Multivariate analysis adjusting for age, gender, tumor location, tumor stage and CIMP and microsatellite instability (MSI) statuses indicated that CIMP-high colon cancers were associated with a significant increase in colon cancer-specific mortality (hazard ratio [HR], 3.23; 95% confidence interval [CI], 1.20 to 8.69; p=0.02). In microsatellite stable cancers, CIMP-high cancer had a poor survival outcome compared to CIMP-low/negative cancer (HR, 2.91; 95% CI, 1.02 to 8.27; p=0.04). Conclusions: Regardless of the MSI status, CIMP-high cancers had poor survival outcomes in Korean patients.
참고문헌 (30)
- Jemal A, "Cancer statistics, 2005", CA Cancer J Clin, 55, pp.10~30 (2005)
- Markowitz SD, "Molecular origins of cancer: molecular basis of colorectal cancer", N Engl J Med, 361, pp.2449~2460 (2009)
- Young S. Kim, "Epigenetic Changes (Aberrant DNA Methylation) in Colorectal Neoplasia", Gut and Liver, 1(1), pp.1~11 (2007), 거트앤리버 발행위원회
- Toyota M, "CpG island methylator phenotype in colorectal cancer", Proc Natl Acad Sci U S A, 96, pp.8681~8686 (1999)
- Issa JP, "CpG island methylator phenotype in cancer", Nat Rev Cancer, 4, pp.988~993 (2004)
- Samowitz WS, "Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers", Cancer Res, 65, pp.6063~6069 (2005)
- Weisenberger DJ, "CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer", Nat Genet, 38, pp.787~793 (2006)
- Jass JR, "Classification of colorectal cancer based on correlation of clinical, morphological and molecular features", Histopathology, 50, pp.113~130 (2007)
- Rashid A, "CpG island methylation in gastroenterologic neoplasia: a maturing field", Gastroenterology, 127, pp.1578~1588 (2004)
- Hawkins N, "CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability", Gastroenterology, 122, pp.1376~1387 (2002)
- van Rijnsoever M, "Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands", Gut, 51, pp.797~802 (2002)
- Samowitz WS, "Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer", Gastroenterology, 129, pp.837~845 (2005)
- Issa JP, "CIMP, at last", Gastroenterology, 129, pp.1121~1124 (2005)
- Kim JH, "Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers", Virchows Arch, 455, pp.485~494 (2009)
- Lee S, "Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS", BRAF mutation, 2008, pp.58, 104~113
- Dahlin AM, "The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status", Clin Cancer Res, 16, pp.1845~1855 (2010)
- Ogino S, "CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer", Gut, 58, pp.90~96 (2009)
- Oh SW, "The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer", Dis Colon Rectum, 51, pp.56~61 (2008)
- Greene FL, "AJCC cancer staging manual" (2002), Springer-Verlag
- Ogino S, "Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis", J Mol Diagn, 8, pp.209~217 (2006)
- Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer", Cancer Res, 58, pp.5248~5257 (1998)
- Loukola A, "Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC)", Cancer Res, 61, pp.4545~4549 (2001)
- Hoang JM, "BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines", Cancer Res, 57, pp.300~303 (1997)
- Issa JP, "Methylation and prognosis: of molecular clocks and hypermethylator phenotypes", Clin Cancer Res, 9, pp.2879~2881 (2003)
- Van Rijnsoever M, "CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer", Clin Cancer Res, 9, pp.2898~2903 (2003)
- Ogino S, "CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma", Virchows Arch, 450, pp.529~537 (2007)
- Shen L, "Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy", Clin Cancer Res, 13, pp.6093~6098 (2007)
- Bae JM, "Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location", Br J Cancer, 109, pp.1004~1012 (2013)
- 오승엽, "산발성 대장암에서 현미부수체 불안정성의 임상병리학적 의의", 대한외과학회지, 71(6), pp.420~425 (2006), 대한외과학회
- Kang KJ, "Adenoma incidence after resection of sporadic colorectal cancer with microsatellite instability", J Surg Oncol, 101, pp.577~581 (2010)